medigraphic.com
ISSN 2225-4676 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Neurol Neurocir 2022; 12 (1)

Tuberous sclerosis complex

Pimienta MM, Cardentey SR, Bravo DJR, García LM, Mesa TJL, García LAB

Language: Spanish
References: 11
Page: 1-12
PDF size: 384.14 Kb.


ABSTRACT

Introduction: Tuberous sclerosis is an autosomal dominant genetic disease with highly variable penetrance, characterized by skin lesions, mental retardation and the appearance of multiple tumors.
Objective: To contribute to the knowledge of this disease with emphasis on the usefulness of clinical knowledge and imaging characteristics for diagnosis.
Case report: We report a 3-month-old female infant, who at 2 months of age began to have paroxysmal events that started with interrupting activity, blinking of the right eye followed by cephalic version to the right, oro-alimentary automatisms and dystonic posture of both upper limbs, during short periods (30 seconds) with spontaneous recovery without sequelae. These events occurred several times a day. Hypomelanotic spots were found on the skin; as well as a confettishaped lesion at the upper dorsal level and left axillary region. Magnetic resonance imaging was performed showing the presence of subependymal nodules and cortical tubercles. Treatment with sodium valproate and Vigabatrin was started with positive evolution.
Conclusions: The case reported is an example of a patient with tuberous sclerosis due to a de novo mutation, with a typical clinical-imaging picture, which allowed the diagnosis; with no history of affected relatives and with improvement favored by the treatment used.


REFERENCES

  1. Gómez Cerdas MT, Vargas Morales JA. Esclerosis tuberosa. Rev Méd Sinergia. 2019; 4(3):21-37. DOI: https://doi.org/10.31434/rms.v4i3.182

  2. Silva González GK, Ochoa Hidalgo AC, Hernández Almaguer BC. Diagnóstico prenatal detumoración cardíaca asociada a esclerosis tuberosa. Rev. electrón. “Dr. Zoilo E. MarinelloVidaurreta”. 2016[acceso 17/07/2021];41(5). Disponible en:https://revzoilomarinello.sld.cu/index.php/zmv/article/view/765

  3. Núñez E, Bonilla Y, Varela D. Actualización de métodos diagnósticos en el Complejo deEsclerosis Tuberosa. Rev Mexicana Neurociencia. 2016 [acceso 17/07/2021];17(4):86-95.Disponible en: https://www.medigraphic.com/cgibin/new/resumen.cgi%3FIDARTICULO%3d69100&ved

  4. Song X, Liu Z, Cappell K, Gregory C, Said Q, Prestifilippo J, et al. Healthcare utilization andcosts in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. J Med Economics.2017;20(4):388-94. DOI: 10.1080/13696998.2016.1272461

  5. Sasongko T, Ismail N, Zabidi-hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database of Systematic Reviews; 2016:1-45. DOI: 10.1002/14651858.CD011272

  6. Herazo Bustos C, Wilches Vanegas C. Complejo de esclerosis tuberosa de diagnóstico tardío.Rev Argent Radiol. 2018;82:131-3. DOI: https://doi.org/10.1055/s-0038-1639380

  7. Torres V, Contreras GA, Serrano N, Páez MC, Guzmán MC. Complejo de la esclerosis tuberosa.Revisión de tema y presentación de caso. Rev Asoc Colomb Dermatol. 2011;19:76-81.

  8. Buj Pradilla MJ, Martí Bellesté T, Torra R, Villacampa Aubá F. Recommendations for imagingbaseddiagnosis and management of renal angiomyolipoma associated with tuberous sclerosiscomplex. Clin Kidney J. 2017;10(6):728-37. Epub 1017 Sep 11. DOI: 10.1093/ckj/sfx094

  9. Fournier Del Castillo MC, Melero Llorente J, Blanco Beregaña M, Robles Bermejo F, BudkeM, García Fernández M, et al. Deterioro neuropsicológico reversible asociado a zonisamida en unpaciente pediátrico con esclerosis tuberosa. Rev Neurol. 2015;60(2):75-80. DOI:https://doi.org/10.33588/rn.6002.2014475

  10. Randell E, Mcnamara R, Davies DM, Owen-Jones E, Kirby N, Angel L, et al. The use ofeverolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON ): studyprotocol for a randomised controlled trial. Trials; 2016 Aug 11;17:398. DOI: 10.1186/s13063-016-1446-6

  11. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors(rapamycin and its analogues) for tuberous sclerosis complex : a meta-analysis. Orphanet J RareDis. 2019;14(1):39. DOI: 10.1186/s13023-019-1012-x




2020     |     www.medigraphic.com